INTEGRATED BIOPHARMA, INC. (INBP) Gross profit 2018–2026
INTEGRATED BIOPHARMA, INC. (INBP) annual gross profit history from SEC filings — each fiscal year as reported.
$800,000FY2026 · since FY2018: $5.0M → $800,000
| Fiscal year | Value | YoY |
|---|---|---|
| FY2026 | $800,000 | -85.6% |
| FY2025 | $5.6M | +43.2% |
| FY2024 | $3.9M | -4.4% |
| FY2023 | $4.1M | -38.0% |
| FY2022 | $6.6M | -30.9% |
| FY2021 | $9.5M | +40.9% |
| FY2020 | $6.7M | +8.1% |
| FY2019 | $6.2M | +24.7% |
| FY2018 | $5.0M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More INBP financial trends
INBP RevenueINBP Net incomeINBP Net marginINBP Gross marginINBP Operating incomeINBP Operating marginINBP Operating cash flowINBP Free cash flowINBP Capital expendituresINBP Return on equityINBP Stock buybacksINBP Dividends paidINBP Total assetsINBP Total liabilitiesINBP Shareholders’ equityINBP overview →